troglitazone has been researched along with Cancer of Granulosa Cells in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mu, YM | 1 |
| Yanase, T | 1 |
| Nishi, Y | 1 |
| Takayanagi, R | 1 |
| Goto, K | 1 |
| Nawata, H | 1 |
1 other study available for troglitazone and Cancer of Granulosa Cells
| Article | Year |
|---|---|
Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells.
Topics: Aromatase; Cell Division; Chromans; Dactinomycin; Dose-Response Relationship, Drug; Down-Regulation; | 2001 |